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STUDY HIGHLIGHTS 
 
WHAT IS CURRENT KNOWLEDGE  
 A minority of Barrett’s esophagus patients will undergo neoplastic progression 
 Few factors have been identified that distinguish Barrett’s esophagus patients at highest 
risk of progression 
 
WHAT IS NEW HERE 
 No short-segment Barrett’s cases developed esophageal adenocarcinoma during the 
study period 
 Ulceration in the Barrett’s segment was associated with an increased risk of neoplastic 
progression 
 Absence of reflux symptoms is not associated with a reduced risk of malignant 
progression 
 
Abstract 
Introduction: Risk stratification of Barrett’s esophagus (BE) patients based on clinical and 
endoscopic features may help to optimise surveillance practice for esophageal adenocarcinoma 
(EAC) development.  The aim of this study was to investigate patient symptoms and 
endoscopic features at index endoscopy and risk of neoplastic progression in a large 
population-based cohort of BE patients. 
Methods: A retrospective review of hospital records relating to incident BE diagnosis was 
conducted in a subset of patients with specialised intestinal metaplasia from the Northern 
Ireland BE register.  Patients were matched to the Northern Ireland Cancer Registry to identify 
progressors to EAC or esophageal high grade dysplasia (HGD).  Cox proportional hazards 
models were applied to evaluate the association between endoscopic features, symptoms and 
neoplastic progression risk. 
Results: During 27,997 person-years of follow-up, 128 of 3,148 BE patients progressed to 
develop HGD/EAC.  Ulceration within the Barrett’s segment, but not elsewhere in the 
esophagus, was associated with an increased risk of progression (HR 1.72; 95%CI: 1.08-2.76).  
Long segment BE carried a significant 7-fold increased risk of progression compared with short 
segment BE; none of the latter group developed EAC during the study period.  A reported 
weight loss of ≥5kg at incident BE was predictive of a doubled risk of progression to cancer, 
even up to 5 years post-diagnosis. Conversely, the absence of reflux symptoms was associated 
with a increased risk of cancer progression (HR 1.61; 95% CI: 1.05-2.46).    
Conclusions:  BE patients presenting with a long segment BE, Barrett’s ulcer or substantial 
weight loss have an increased risk of progressing to HGD/EAC and should be considered for 
more intense surveillance.  The absence of reflux symptoms at BE diagnosis is not associated 
with a reduced risk of malignant progression, and may carry an increased risk of progression.  
Introduction 
Barrett’s esophagus (BE), metaplasia of the normal esophageal squamous epithelium into 
specialised columnar epithelium, is rising in incidence (over and above endoscopy rates) 
throughout the Western world.(1-3)  The importance of BE lies in the fact that it is a precursor 
of esophageal adenocarcinoma (EAC), a tumor that has a poor prognosis.(4, 5) The opportunity 
for detection of BE, and potential prevention of adenocarcinoma, has led gastroenterology 
organisations worldwide to endorse endoscopic surveillance of BE patients.(6, 7)  However, 
endoscopic surveillance of BE is controversial due to ongoing debate as to its cost 
effectiveness.(8) Identifying patients at greatest risk of neoplastic progression, which only 
occurs in a minority of cases,(9-11) is a key priority in order to optimise the usefulness of such 
surveillance programmes. 
 
BE and EAC are both thought to result from repeated exposure to bile and gastric acid in the 
distal esophagus.(12)  A landmark publication from a Swedish population-based case-control 
study demonstrated that individuals reporting weekly reflux symptoms were at a 7-fold 
increased risk of EAC.(13) Moreover, a dose-response relationship with frequency of 
symptoms was also noted.(13)  However, in contrast to the link between symptoms in the 
general population and development of EAC, the relationship between reflux symptoms 
experienced at presentation of BE and subsequent risk of neoplastic progression is less 
certain.(14)  
 
BE is thought to represent an adaptive response to acid-induced injury and ulceration and 
therefore it is not unexpected that a substantial proportion of BE patients purport to be 
asymptomatic.(15)  The relevance of reflux, and other, symptoms present BE at diagnosis for 
stratification of cancer risk and associated need for surveillance is yet to be determined.  
Stratification of patients for surveillance based on other endoscopic findings at BE 
presentation, such as esophagitis and ulceration, has also been suggested by some studies.(14, 
16)  However, previous studies seeking to explore the association between these findings and 
EAC risk in a sequential manner have been limited by relatively small numbers of outcomes 
or lack of adjustment for known confounders, such as the presence of low grade dysplasia.(14, 
16) 
 
The aim of this study was to examine the association between symptoms and endoscopic 
features in incident BE patients and their risk of neoplastic progression in a large population 
based cohort.  
 
 
 
 
 
 
 
 
Methods 
Data collection 
BE patients with specialised intestinal metaplasia (SIM) were identified from the Northern 
Ireland BE register, which is a population-based register of all individuals aged ≥16 years who 
were diagnosed with columnar-lined epithelium of the esophagus since 1993 in the province.(1)  
The register excludes BE cases with prevalent HGD, but retains those with indefinite or low-
grade dysplasia at incident BE diagnosis. Between 1993 and 2005, 4,717 BE patients were 
diagnosed with SIM, of whom 3,167 (comparable in age and sex distribution to all SIM 
patients) underwent a hospital case note review.  The hospital notes of these patients were 
retrospectively reviewed by one of three trained data abstractors between March 2005 and 
March 2010.  A standardised electronic proforma in Microsoft Access was utilised to extract 
demographic, medical, symptom, treatment and clinical information from records 
corresponding to the patient’s incident diagnosis of BE.  The process of this case note review 
has been previously described for outcomes up to the end of 2008.(17)  The Northern Ireland 
BE register has subsequently been populated with the Health and Social Care number (a unique 
identifier within the UK National Health Service).  This allowed identification of a small 
number of duplicate patients (n=19, 0.6%), leaving 3,148 BE patients in the current analysis.   
 
Confirmation of outcome diagnosis 
Details of the linkage process and confirmation of BE patients who progressed to develop 
cancer and high grade dysplasia (HGD) in this cohort have been published elsewhere.(9)  
Briefly, the Northern Ireland BE register was linked to the Northern Ireland Cancer Registry 
to identify patients diagnosed with incident esophageal and gastric cardia adenocarcinomas or 
unspecified cancers of the esophagus on or before 31st December 2010.  Esophageal squamous 
cell carcinomas were excluded.  Cases of HGD were identified from an electronic and manual 
review of all esophageal biopsy reports within Northern Ireland up to 31st December 2010.  
Only cancers or HGD diagnosed at least six months after an incident BE diagnosis were 
included, to minimise the potential for prevalent cancers to have influenced symptom 
experience and endoscopic features.  The Northern Ireland BE register was matched to the 
General Registrar’s Office in Northern Ireland to identify deaths occurring over the same time 
period. 
 
Statistical analysis 
Independent t-tests and chi-squared tests were applied to compare continuous and categorical 
variables, respectively, between BE patients who progressed to cancer or HGD and those who 
did not progress.  Where the report relating to an incident BE diagnosis did not mention a 
symptom or endoscopic feature, for example gastrointestinal bleeding, that patient was 
presumed to not have experienced that symptom or feature and was recoded accordingly.  Cox 
proportional hazards models were applied to investigate the association between reported 
symptoms and endoscopic features at incident BE diagnosis and the risk of progression to 
cancer or HGD.  Assumptions for Cox proportional hazards models were checked by visual 
inspection of Kaplan Meier plots.  Both unadjusted and adjusted models were applied, using a 
censor date as the date of death, date of cancer or HGD diagnosis or 31st December 2010.  In 
adjusted models, included confounders were age, sex, presence of low-grade dysplasia, socio-
economic status (reflected by area-based income deprivation quintiles), tobacco smoking status 
(never/former/current/unknown) and Barrett’s segment length, based on a priori knowledge of 
these risk factors for EAC development.  We also tested adjustment for ever use of medications 
including non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, proton pump inhibitors 
(PPIs) and H2 antagonists but these did not significantly alter the results shown.  Stratified 
analyses were conducted for cancer only outcomes by follow-up duration, age categories, 
Barrett’s segment length, smoking status, PPI usage and dysplastic status.  Tests for 
interactions were conducted using the likelihood ratio test.  In addition, sensitivity analyses 
excluding outcomes diagnosed within one year of follow-up were conducted to minimise the 
likelihood of reverse causation from undetected prevalent neoplasms.  All statistical analysis 
was conducted using Intercooled Stata Version 11 (StataCorp, Texas, USA).   
 
Results 
 
A total of 3,148 BE patients were followed for a mean (±SD) of 8.9 (±4.1) years (range 0.5-
18.0 years).  During this period, 128 patients progressed to develop HGD (n=36) or EAC 
(n=92).  Demographic, lifestyle and clinical data of these patients are displayed in Table 1.  
Progressors were more likely to be male, aged 60-70 years at incident BE, have long-segment 
BE, low-grade dysplasia and have ever smoked tobacco compared with non-progressors.  No 
significant differences were observed between progressors and non-progressors in terms of 
socio-economic status or usage of certain medications (NSAIDs, aspirin, H2 antagonists or 
PPIs) at their incident BE diagnosis.  
 
Table 2 outlines the association between esophageal features noted at endoscopy and the risk 
of neoplastic progression in incident BE.  Long segment Barrett’s was associated with a seven-
fold increased risk of progression, although segment length was unknown in approximately 
half of patients.  Only two patients with short-segment BE progressed to HGD, with none 
developing EAC during the study time period.  Progressors were more likely to have had a 
Barrett’s ulcer at their incident diagnosis compared with non-progressors (HR 1.99; 95% CI: 
1.26-3.15), even after adjustment for confounders (HR 1.72; 95% CI: 1.08-2.76).  Other 
endoscopic features, including esophagitis, esophageal stricture, and presence of hiatus hernia, 
were unrelated to progression risk.  Largely similar results were observed in analysis including 
only cancer progressors (Table 2).   
 
The association between reported symptoms at incident BE diagnoses and the risk of 
progression is shown in Table 3.  Incident BE patients reporting gastro-esophageal reflux 
symptoms had a reduced risk of cancer progression (HR 0.62; 95% CI: 0.41-0.95).  This was 
equivalent to asymptomatic patients having a 61% increased risk of EAC progression, after 
adjustment for confounders (HR 1.61; 95% CI: 1.05-2.46).  The association was weaker when 
considering HGD and EAC outcomes combined.  BE patients reporting ≥5kg loss in body 
weight at their incident diagnosis were at a significantly increased risk of cancer progression 
(HR 2.01; 95% CI: 1.01-3.98) compared with patients who did not report experiencing weight 
loss.  No other reported symptoms were associated with progression risk. 
 
A priori sensitivity and stratified analyses 
As shown in Supplementary Figure 1, the magnitude of the inverse association between reflux 
symptoms and EAC progression risk remained consistent across strata of follow-up time, age 
categories, BE segment length, smoking status, PPI usage and in non-dysplastic BE at index 
diagnosis.  Small numbers precluded meaningful sensitivity and stratified analyses for weight 
loss and Barrett’s ulceration findings.  Nevertheless, it should be noted that the direct 
association between a reported weight loss of ≥5kg and cancer progression remained even up 
to five years post-incident BE diagnosis (HR 3.09; 95% CI: 1.27-7.53).   
 
All previously observed associations remained largely unaltered in sensitivity analyses of 
patients whose esophageal HGD or cancer was diagnosed at least one year after their incident 
BE diagnosis (Table 4). 
 
 
 
Discussion 
In the present study, based on one of the largest series of progressors from BE to HGD/EAC 
in the world, the presence of long-segment Barrett’s carried a seven-fold increased risk of 
progression.  Smaller, but statistically significant, increased risks of progression were also 
noted for patients with Barrett’s ulceration and for those reporting substantial weight loss at 
their incident diagnosis.  Gastro-esophageal reflux symptoms were associated with a decreased 
risk of cancer progression, while no other reported symptoms or endoscopic findings were 
predictive of progression in these patients. 
 
Due to the relatively low proportion of BE patients who progress to HGD/EAC,(9) research 
efforts are attempting to identify factors that may streamline the entry into surveillance and its 
frequency.  The relevance of both symptoms at presentation and endoscopic findings at BE 
diagnosis are of importance to clinicians when considering entry into surveillance and risk of 
malignant progression with individual patients.(18)    
 
A study of 27 BE patients undergoing 24 hour esophageal pH monitoring has previously 
identified a strong positive correlation between the duration of acid exposure and Barrett’s 
segment length.(19)  One of the key findings from the current study was that patients with long 
segment BE (defined as ≥3cm) had a seven-fold increased risk of progression to HGD/EAC 
compared with short segment Barrett’s.  Our analysis was somewhat limited though, since 
Barrett’s segment length was unknown in almost half of patients.  The finding that longer 
segment length corresponds to increased progression risk concurs with results from several 
other studies(20-22) and previous reports from this cohort.(9)  The lack of progression in short-
segment BE cases suggests that there would be limited benefits to entering these patients into 
current surveillance protocols, and that longer surveillance intervals or additional criteria for 
inclusion in surveillance programs may be warranted.(23)    
 
In addition, our findings demonstrated that the presence of Barrett’s ulceration, but not 
ulceration elsewhere in the esophagus, increased the risk of progression to HGD/EAC.  
Because our study is large, it builds upon observations from previous smaller studies, affording 
greater specificity of findings.  In an Australian study of 353 BE patients, of whom 13 
progressed to HGD/EAC over a 20 year follow-up period, the combined presence of severe 
esophagitis, nodularity, Barrett’s ulceration and/or stricture was deemed to elevate the risk of 
progression in age- and sex-adjusted analysis.(16)  A small study reported by Switzer-Taylor 
et al (2008), in which 9 esophageal cancers were detected amongst a sample of 212 BE patients 
during 13 years of follow-up, noted that half of progressors had ulceration at their index 
endoscopy.(24)  A Dutch study of 713 patients, incorporating 26 progressors, found BE 
‘irregularities’ (incorporating erosions, ulcers and nodules) to carry a non-significant 2-fold 
increased risk of progression in multivariate models, while esophagitis was a determinant of 
progression.(14) A recent report from the North-Eastern Italian BE register also noted 
ulceration or nodularity to be associated with a heightened risk of HGD/EAC in analysis of 22 
progressors.(25) 
 
Case-control studies have identified that reflux symptoms in the general population are linked 
with esophageal carcinogenesis.(12, 26, 27)   That is consistent with the well-established role 
of reflux in BE development.(28, 29)  By contrast, asymptomatic BE patients in the current 
study were found to be at greater risk of EAC progression, and whom a recent review 
highlighted to have an unknown prognosis.(30)  In turn, these findings point to the presence of 
reflux symptoms at the time of diagnosis of BE diagnosis as being inversely associated with 
progression risk.  It is highly unlikely that this reflects a ‘true’ decreased risk, since mechanistic 
evidence supports the carcinogenic effects of chronic acid exposure in Barrett’s cell lines, such 
as inflammation and induction of chromosomal aneuploidy,(31) which is predictive of BE 
progression risk.(32)   
 
Rather, it is more plausible that a poor correlation exists between patient perception of reflux 
and actual refluxate in the esophagus.  Symptoms of gastro-esophageal reflux disease are not 
predictive of BE presence,(33) and it has long been known that there is reduced esophageal 
acid sensitivity in columnar versus squamous mucosa.(34)  A small pain-stimulation study has 
also demonstrated that BE patients are hyposensitive to heat in both the normal squamous and 
the metaplastic epithelium of their esophagus compared with normal controls,(35) hence may 
be less likely to report symptoms.  Our results suggested this was not reflective of age 
disparities in symptom recognition, as has been postulated by others.(36, 37)  The relationship 
between symptoms and acid exposure is an important area for further research, since our 
findings suggest that subjectively reported symptoms would not be useful in stratifying high-
risk BE patients for surveillance. Moreover, our results also raise questions over symptom 
control being the desired endpoint in BE management, as has been highlighted by Sarela and 
colleagues.(38)  Asymptomatic patients may still require anti-acid treatments.  
 
In addition, we observed that weight loss of ≥5kg in BE patients was associated with a 
significantly increased risk of progression.  It is unlikely that such weight loss was reflecting 
subclinical disease, or the development of more aggressive tumors amongst BE progressors, 
since progression risk remained elevated up to five years after BE diagnosis.   Such substantial 
weight loss could reflect prior overweight/obesity, which is a known risk factor for esophageal 
adenocarcinoma.(12, 39)  It is important for future prospective studies to distinguish the intent, 
nature and timing of weight loss.  This is necessary to avoid detracting from the public health 
message that individuals should maintain a normal body weight in order to reduce their risk of 
developing EAC.(39, 40)  
 
Our study has several strengths, including its large size and population-based setting in the 
Northern Ireland BE register, providing generalisability to all BE patients in the province. 
Although information was collected retrospectively, it was retrieved from hospital case notes 
relating to a patient’s incident BE diagnosis.  Therefore, this is the largest study to date that has 
investigated endoscopic findings and symptom experiences and progression risk in a sequential 
manner. In addition, we were able to control for a number of known confounders in our 
analysis. 
 
There are some limitations to our analysis.  It is possible that some patients did not report all 
of their symptoms to clinicians in order for them to be recorded in the case notes.  The 
potentially subjective nature of symptoms reporting means that results for reflux symptoms 
and weight loss should be interpreted with caution.  Our analysis of Barrett’s segment length 
was relatively crude as we did not have exact length in cm for most patients and length was 
unknown for a considerable proportion.  It is also plausible that there may be some residual 
confounding from unaccounted variables in our analysis. 
 
In conclusion, BE patients presenting with long segment Barrett’s, Barrett’s ulceration or 
substantial weight loss have an increased risk of progressing to HGD/EAC and should be 
considered for more intense surveillance.  The absence of reflux symptoms at diagnosis is not 
associated with a reduced risk of malignant progression, and may carry an increased risk of 
progression. 
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Table 1. Descriptive characteristics of patients at their index Barrett’s esophagus diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Low grade or indefinite dysplasia; NSAIDs: Non-steroidal anti-inflammatory drugs; H2 Antagonists; 
PPIs: Proton pump inhibitors.   
 
 
 
 
 
 
Characteristics Non-
progressors 
(n =3,023) 
Progressors 
 
(n=128) 
 
P-value 
 
Mean age at Barrett’s diagnosis 
(years) 
 
62.0 ± 14.1 
 
62.1 ± 11.5 
 
 
0.98 
Age group (years) 
  16-<40 
  40-<50 
  50-<60 
  60-<70 
  70-<80 
  ≥80 
 
195    (6.5) 
432    (14.3) 
681    (22.5) 
753    (24.9) 
643    (21.3) 
319    (10.5) 
 
4    (3.1) 
14  (10.9) 
31  (24.2) 
49  (38.3) 
24  (18.8) 
6    (4.7) 
 
 
 
0.006 
Sex  
  Male 
  Female 
 
1,881  (62.2) 
1,142  (37.8) 
 
99  (77.3) 
29  (22.7) 
 
0.001 
Barrett’s segment length 
  Short, <3cm 
  Long, ≥3cm 
  Unknown 
 
323     (10.7) 
1,316  (43.5) 
1,384  (45.8) 
 
2    (1.6) 
71  (55.5) 
55  (43.0) 
 
 
0.001 
Presence of dysplasia* 
  Yes 
  No 
  Unknown 
 
182     (6.0) 
2,602  (86.1) 
239     (7.9) 
 
31  (24.2) 
83  (64.8) 
14  (11.0) 
 
 
<0.001 
Income deprivation quintile 
  I   (Most deprived) 
  II 
  III 
  IV 
  V (Least deprived) 
  Unknown 
 
638     (21.1) 
598     (19.8) 
531     (17.6) 
521     (17.2) 
460     (15.2) 
275     (9.1) 
 
28  (21.9) 
33  (25.8) 
22  (17.2) 
14  (10.9) 
23  (18.0) 
8    (6.2) 
 
 
0.23 
Smoking status 
  Never 
  Former 
  Current 
  Unknown 
 
1,394  (46.1) 
619     (20.5) 
712     (23.5) 
298     (9.9) 
 
47  (36.7) 
33  (25.8) 
44  (34.4) 
4    (3.6) 
 
 
0.001 
Ever use of medications 
  NSAIDs 
  Aspirin 
  H2 Antagonists 
  PPIs 
 
212     (7.0) 
495     (16.4) 
437     (14.5) 
1,378  (45.6) 
 
8    (6.3) 
15  (11.7) 
23  (18.0) 
58  (45.3) 
 
0.74 
0.16 
0.27 
0.95 
Table 2. Endoscopic features at incident BE diagnosis and risk of neoplastic progression.  
 
*Incorporates patients recorded as having esophagitis or ulceration in an area of the esophagus other than their Barrett’s segment. 
Adjustments: age groups (16-<40/40-<50/50-<60/60-<70/70-<80/≥80 years), sex (male/female), presence of low grade dysplasia (yes/no/unknown), income deprivation 
quintile (I/II/III/IV/V/unknown), Barrett’s segment length (long/short or unknown) (except Length of Barrett’s analysis), smoking status (never/former/current/unknown).  
Risk factors Non-
progressors 
(n =3,020) 
All 
Progressors 
(n=128) 
Unadjusted 
Hazard ratio 
(95% CI) 
 
 
P trend 
Adjusted 
Hazard ratio 
(95% CI) 
 
 
P trend 
EAC 
Progressors 
(n=92) 
Adjusted 
Hazard ratio 
(95% CI) 
 
 
P trend 
Length of Barrett’s 
  Short (<3cm) 
  Long (≥3cm) 
  Unknown 
 
323    (10.7) 
1,314 (43.5) 
1,383 (45.8) 
 
2     (1.5) 
71   (55.5) 
55   (43.0) 
 
1.00 
8.24 (2.02-33.58) 
6.23 (1.52-25.56) 
 
 
0.004 
 
1.00 
7.10 (1.74-29.04) 
5.82 (1.42-23.94) 
 
 
0.003 
 
0     (0.0) 
53   (57.6) 
39   (42.4) 
 
/ 
 
/ 
Barrett’s ulcer 
  No/unknown 
  Yes 
 
2,748 (91.0) 
272    (9.0) 
 
106 (82.8) 
22   (17.2) 
 
1.00 
1.99 (1.26-3.15) 
 
 
0.003 
 
1.00 
1.72 (1.08-2.76) 
 
 
0.02 
 
75   (81.5) 
17   (18.5) 
 
1.00 
1.83 (1.07-3.13) 
 
 
0.03 
Esophagitis*  
  No/unknown 
  Yes 
 
1,760 (58.3) 
1,260 (41.7) 
 
83   (64.8) 
45   (35.2) 
 
1.00 
0.74 (0.52-1.07) 
 
 
0.11 
 
1.00 
0.77 (0.53-1.12) 
 
 
0.18 
 
56   (60.9) 
36   (39.1) 
 
1.00 
0.97 (0.63-1.49) 
 
 
0.88 
Esophageal stricture seen 
  No/unknown 
  Yes 
 
2,811 (93.1) 
209    (6.9) 
 
115 (89.8) 
13   (10.2) 
 
1.00 
1.56 (0.88-2.78) 
 
 
0.13 
 
1.00 
1.65 (0.92-2.95) 
 
 
0.09 
 
83   (90.2) 
9     (9.8) 
 
1.00 
1.59 (0.79-3.21) 
 
 
0.19 
Hiatus hernia 
  No/unknown 
  Yes 
 
1,283 (42.5) 
1,737 (57.5) 
 
56   (43.8) 
72   (56.3) 
 
1.00 
0.90 (0.63-1.28) 
 
 
0.56 
 
1.00 
0.95 (0.67-1.36) 
 
 
0.79 
 
41   (44.6) 
51   (55.4) 
 
1.00 
0.92 (0.60-1.39) 
 
 
0.68 
Table 3. Reported symptoms at incident BE diagnosis and risk of neoplastic progression.  
 
GI Bleeding: Gastrointestinal bleeding. 
Adjustments: age groups (16-<40/40-<50/50-<60/60-<70/70-<80/≥80 years), sex (male/female), presence of low grade dysplasia (yes/no/unknown), income 
deprivation quintile (I/II/III/IV/V/unknown), Barrett’s segment length (long/short or unknown), smoking status (never/former/current/unknown). 
 
 
 
Risk factors Non-
progressors 
(n =3,020) 
All 
Progressors 
(n=128) 
Unadjusted 
Hazard ratio 
(95% CI) 
 
 
P trend 
Adjusted 
Hazard ratio 
(95% CI) 
 
 
P trend 
EAC 
Progressors 
(n=92) 
Adjusted 
Hazard ratio 
(95% CI) 
 
 
P trend 
Presence of reflux 
  No/unknown  
  Yes 
 
1,392 (46.1) 
1,628 (53.9) 
 
57  (44.5) 
71  (55.5) 
 
1.00 
0.85 (0.60-1.21) 
 
 
0.36 
 
1.00 
0.76 (0.53-1.09) 
 
 
0.13 
 
45  (48.9) 
47  (51.1) 
 
1.00 
0.62 (0.41-0.95) 
 
 
0.03 
GI bleeding 
  No/unknown 
  Yes 
 
2,652 (87.8) 
368    (12.2) 
 
115 (89.8) 
13   (10.2) 
 
1.00 
0.97 (0.54-1.72) 
 
 
0.91 
 
1.00 
0.95 (0.54-1.70) 
 
 
0.88 
 
80   (87.0) 
12   (13.0) 
 
1.00 
1.26 (0.68-2.34) 
 
 
0.46 
Anaemia 
  No/unknown 
  Yes 
 
2,630 (87.1) 
390    (12.9) 
 
112 (87.5) 
16   (12.5) 
 
1.00 
1.14 (0.67-1.92) 
 
 
0.63 
 
1.00 
1.25 (0.72-2.14) 
 
 
0.43 
 
78   (84.8) 
14   (15.2) 
 
1.00 
1.45 (0.80-2.64) 
 
 
0.22 
Dysphagia 
  No/unknown 
  Yes 
 
2,357 (78.0) 
663    (22.0) 
 
97   (75.8) 
31   (24.2) 
 
1.00 
1.10 (0.74-1.65) 
 
 
0.64 
 
1.00 
1.21 (0.80-1.82) 
 
 
0.36 
 
70   (76.5) 
22   (23.5) 
 
1.00 
1.20 (0.74-1.95) 
 
 
0.45 
Nausea & vomiting 
  No/unknown 
  Yes 
 
2,194 (72.7) 
826    (27.3) 
 
94   (73.4) 
34   (26.6) 
 
1.00 
1.02 (0.69-1.51) 
 
 
0.92 
 
1.00 
1.06 (0.71-1.57) 
 
 
0.79 
 
64   (69.6) 
28   (30.4) 
 
1.00 
1.26 (0.80-1.97) 
 
 
0.31 
Weight loss 
  No/unknown 
  Yes, <5kg/unknown  
  Yes, >5kg 
 
2,620 (86.7) 
205    (6.8) 
195    (6.5) 
 
108 (84.4) 
8     (6.3) 
12   (9.4) 
 
1.00 
1.04 (0.50-2.12) 
1.81 (0.99-3.28) 
 
 
 
0.08 
 
1.00 
0.96 (0.46-2.00) 
1.65 (0.89-3.05) 
 
 
 
0.17 
 
76  (82.6) 
6    (6.5) 
10  (10.9) 
 
1.00 
1.03 (0.44-2.40) 
2.01 (1.01-3.98) 
 
 
 
0.07 
Epigastric pain 
  No/unknown 
  Yes 
 
1,852 (61.3) 
1,168 (38.7) 
 
75   (58.6) 
53   (41.4) 
 
1.00 
1.04 (0.73-1.47) 
 
 
0.85 
 
1.00 
0.99 (0.70-1.42) 
 
 
0.97 
 
55   (59.8) 
37   (40.2) 
 
1.00 
0.95 (0.63-1.46) 
 
 
0.83 
Table 4. Endoscopic features and reported symptoms and risk of neoplastic progression at least one year after 
incident BE diagnosis. 
 
 
*Incorporates patients recorded as having esophagitis or ulceration in an area of the esophagus other than their 
Barrett’s segment. 
Adjustments: age groups (16-<40/40-<50/50-<60/60-<70/70-<80/≥80 years), sex (male/female), presence of 
low grade dysplasia (yes/no/unknown), income deprivation quintile (I/II/III/IV/V/unknown), Barrett’s segment 
length (long/short or unknown) (except Length of Barrett’s analysis), smoking status 
(never/former/current/unknown).  
Risk factors Non-
progressors 
(n =2,976) 
All 
Progressors 
(n=114) 
Adjusted 
Hazard ratio 
(95% CI) 
 
P 
trend 
EAC 
Progressors 
(n=83) 
Adjusted 
Hazard ratio 
(95% CI) 
 
P 
trend 
Length of Barrett’s 
  Short (<3cm) 
  Long (≥3cm) 
  Unknown 
 
321    (10.8) 
1,291 (43.4) 
1,364 (45.8) 
 
2     (1.8) 
68   (59.7) 
44   (38.6) 
 
1.00 
7.00 (1.71-28.64) 
4.72 (1.14-19.53) 
 
 
0.007 
 
0     (0.0) 
51   (61.4) 
32   (38.6) 
 
/ 
 
/ 
Barrett’s ulcer 
  No/unknown 
  Yes 
 
2,712 (91.1) 
264    (8.9) 
 
94   (82.5) 
20   (17.5) 
 
1.00 
1.70 (1.04-2.79) 
 
 
0.04 
 
67   (80.7) 
16   (19.3) 
 
1.00 
1.89 (1.08-3.30) 
 
 
0.03 
Esophagitis*  
  No/unknown 
  Yes 
 
1,732 (58.2) 
1,244 (41.8) 
 
76   (66.7) 
38   (33.3) 
 
1.00 
0.74 (0.49-1.10) 
 
 
0.14 
 
51   (61.4) 
32   (38.6) 
 
1.00 
0.97 (0.61-1.53) 
 
 
0.89 
Esophageal stricture seen 
  No/unknown 
  Yes 
 
2,768 (93.0) 
208    (7.0) 
 
106 (93.0) 
8     (7.0) 
 
1.00 
1.18 (0.57-2.43) 
 
 
0.66 
 
78   (94.0) 
5     (6.0) 
 
1.00 
0.99 (0.40-2.47) 
 
 
0.98 
Hiatus hernia 
  No/unknown 
  Yes 
 
1,261 (42.4) 
1,715 (57.6) 
 
48   (42.1) 
66   (57.9) 
 
1.00 
0.96 (0.66-1.39) 
 
 
0.82 
 
36   (43.4) 
47   (56.6) 
 
1.00 
0.92 (0.59-1.44) 
 
 
0.72 
Presence of reflux 
  No/unknown  
  Yes 
 
1,353 (45.5) 
1,623 (54.5) 
 
48  (42.1) 
66  (57.9) 
 
1.00 
0.82 (0.56-1.20) 
 
 
0.30 
 
39  (47.0) 
44  (53.0) 
 
1.00 
0.66 (0.42-1.03) 
 
 
0.07 
GI bleeding 
  No/unknown 
  Yes 
 
2,623 (88.1) 
353    (11.9) 
 
102 (89.5) 
12   (10.5) 
 
1.00 
1.03 (0.56-1.88) 
 
 
0.92 
 
72   (86.7) 
11   (13.3) 
 
1.00 
1.35 (0.71-2.57) 
 
 
0.36 
Anaemia 
  No/unknown 
  Yes 
 
2,603 (87.5) 
373    (12.5) 
 
101 (88.6) 
13   (11.4) 
 
1.00 
1.11 (0.61-2.02) 
 
 
0.63 
 
71   (85.5) 
12   (14.5) 
 
1.00 
1.36 (0.72-2.57) 
 
 
0.35 
Dysphagia 
  No/unknown 
  Yes 
 
2,321 (78.0) 
655    (22.0) 
 
89   (78.1) 
25   (21.9) 
 
1.00 
1.08 (0.69-1.69) 
 
 
0.75 
 
65   (78.3) 
18   (21.7) 
 
1.00 
1.07 (0.63-1.81) 
 
 
0.80 
Nausea & vomiting 
  No/unknown 
  Yes 
 
2,166 (72.8) 
810    (27.2) 
 
83   (72.8) 
31   (27.2) 
 
1.00 
1.11 (0.73-1.68) 
 
 
0.62 
 
57   (68.7) 
26   (31.3) 
 
1.00 
1.34 (0.84-2.14) 
 
 
0.22 
Weight loss 
  No/unknown 
  Yes, <5kg/unknown  
  Yes, >5kg 
 
2,585 (86.9) 
200    (6.7) 
191    (6.4) 
 
97   (85.1) 
6     (5.3) 
11   (9.7) 
 
1.00 
0.83 (0.36-1.90) 
1.78 (0.93-3.39) 
 
 
 
0.17 
 
70  (84.3) 
4    (4.8) 
9    (10.8) 
 
1.00 
0.77 (0.28-2.14) 
2.08 (1.01-4.27) 
 
 
 
0.12 
Epigastric pain 
  No/unknown 
  Yes 
 
1,819 (61.1) 
1,157 (38.9) 
 
67   (58.8) 
47   (41.2) 
 
1.00 
0.98 (0.67-1.43) 
 
 
0.91 
 
49   (59.6) 
34   (41.0) 
 
1.00 
0.97 (0.62-1.52) 
 
 
0.90 
